This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical siteSearch

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Click here for VELSIPITY▼ (etrasimod) Prescribing Information. Adverse event reporting can be found at the bottom of the page.

 Home

Menu

Close

Unmet NeedEfficacyEfficacy Home PageTrial DesignClinical RemissionEndoscopic ImprovementCorticosteroid-Free RemissionIsolated ProctitisBio/JAKi Subgroups DataInduction RespondersSymptomatic ResponseBowel UrgencySafetyAdverse eventsPooled and Interim Safety DataSpecial Warnings and PrecautionsCardiac and Ocular Adverse ReactionsGetting StartedGetting StartedContraindications and Interactions

Pre-first Dose TestingResourcesEventsMaterialsVideos

VELSIPITY is indicated for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.1
Symptomatic Responsewithin the first 28 days of ELEVATE UC 52 and 
ELEVATE UC 12 (post hoc analysis)2 ReferencesAdjusted differences were based on estimated common risk difference using Mantel–Haenszel weights and stratified by 
actual naïve to biologic/JAKi therapy at study entry (Yes/No), actual baseline corticosteroid use (Yes/No), and actual baseline disease activity (an mMS of 4 to 6 or an mMS of 7 to 9).2The Mantel–Haenszel weighted test was used to assess the adjusted risk differences in proportions of responders between treatment groups.2Adapted from Dubinsky MC et al. 2023.2Limitations: Results of this post hoc analysis should be evaluated with caution, as head-to-head, randomised trials provide the most reliable comparative efficacy evidence. This was a post hoc analysis of daily e-diary data collected on RB and SF from patients  enrolled in the ELEVATE UC 52 and ELEVATE UC 12 trials. Daily Mayo RB and SF subscores and partial modified Mayo score (pMMS; RB subscore + SF subscore) as well as change from baseline during the first 28 days of therapy were calculated from patient e-diary responses. The Mantel-Haenszel weighted test was used to assess the adjusted risk differences in proportions of responders between treatment groups.2,3Symptomatic response was defined as patients with a ≥30% change from baseline decrease in pMMS.2

Bowel urgency


Read about bowel urgency and 
VELSIPITY.

SEE BOWEL URGENCY DATALoadingCI – confidence interval; JAKi – janus kinase inhibitor; mMS – modified Mayo score; pMMS – partial modified Mayo score; RB – rectal bleeding; SF – stool frequency.References:
1. VELSIPITY Summary of Product Characteristics 
2. Dubinsky MC et al. Poster presented at the United European Gastroenterology Week 2023, Copenhagen, Denmark 
3. Sandborn WJ et al. Lancet 2023;401(10383):1159-1171.Efficacy
PP-V1A-GBR-0020. August 2024

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
You are now leaving PfizerPro​​​​​
​
You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​